Trial Profile
Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Acute asthma; Allergic asthma
- Focus Registrational; Therapeutic Use
- Acronyms MITRA
- Sponsors ALK-Abello
- 30 Dec 2023 Results investigating whether genetic and type 2 (T2) inflammatory biomarkers correlate with disease severity in subjects with allergic asthma, and whether this can be modified by AIT, published in the Thorax
- 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 26 Apr 2016 Results published in the JAMA: the Journal of the American Medical Association